Lombard Medical Ord (EVAR) 0.94 $EVAR
Lombard Medical Reports 2016 Second Quarter, Six-Month Financial Results and Provides Update on Strategic Initiatives
GlobeNewswire - Mon Aug 22, 3:00PM CDT
Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs), today reported financial results, provided business highlights for the second quarter and six months ended June 30, 2016, and announced a significant operational restructuring and the exploration of strategic alternatives to enhance shareholder value.
EVAR: 0.94 (+0.08)
Lombard Medical Reschedules 2016 Second Quarter, Six-Month Financial Results Release and Conference Call Date to August 22 to Provide Complete Information on Operational Initiatives
GlobeNewswire - Fri Aug 12, 3:00PM CDT
Lombard Medical, Inc. (Nasdaq:EVAR), a medical device company focused on Endovascular Aortic Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that it has rescheduled the date to report its 2016 Second Quarter, Six-Month Financial Results to Monday, August 22, 2016, in order to provide complete information on operational initiatives that are underway, but will not be fully implemented until next week. In addition to details on those initiatives, management will discuss financial results and provide a business update on a conference call with the investment community at 4:30 p.m. Eastern Time on Monday, August 22, 2016. Note that as a foreign private issuer, Lombard is not subject to the quarterly reporting requirements of the Securities and Exchange Commission and as such, is not subject to SEC quarterly reporting timelines.
EVAR: 0.94 (+0.08)
Lombard Medical Announces 2016 Second Quarter, Six-Month Financial Results Release and Conference Call Date
GlobeNewswire - Mon Aug 08, 5:00AM CDT
Lombard Medical, Inc. (Nasdaq:EVAR), a medical device company focused on Endovascular Aortic Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that it will release its 2016 second quarter and six-month financial results after the market closes on Monday, August 15, 2016. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Monday, August 15, 2016, to discuss financial results and provide a business update.
EVAR: 0.94 (+0.08)
Lombard Medical Announces CE Mark Approval for IntelliFlex(TM) LP Delivery System for the Aorfix(TM) Abdominal Aortic Aneurysm Endovascular Stent Graft
GlobeNewswire - Mon Jun 20, 11:29AM CDT
Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that it has received CE Mark approval for its IntelliFlex(TM) Low Profile (LP) Delivery System for the Aorfix(TM) Endovascular Stent Graft. This new and innovative system will be used for the delivery of the Aorfix endovascular stent graft, the only AAA stent graft with global approval to treat aortic neck angulation up to 90 degrees. The Company plans to begin shipments in July to its direct markets in the UK and Germany, and expects a full commercial launch in the other European markets later in the year.
EVAR: 0.94 (+0.08)
Lombard Medical Reports Positive Five-Year Aorfix(TM) Endovascular Stent Graft Clinical Results in AAA Patients with Challenging Anatomy
GlobeNewswire - Mon Jun 13, 5:00AM CDT
Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced positive clinical results from The Prospective Aneurysm Trial: High Angle Aorfix(TM) Bifurcated Stent Graft (PYTHAGORAS trial) at the 2016 Society for Vascular Surgery Annual Meeting in National Harbor, Maryland. The PYTHAGORAS trial is a prospective, controlled, multicenter U.S. trial designed to evaluate the safety and effectiveness of the Aorfix endograft for the treatment of highly angulated aortic necks or tortuous aortoiliac anatomy.
EVAR: 0.94 (+0.08)
Lombard Medical Provides Update on Controlled Launch of the New Altura(R) Endovascular Stent Graft in Europe
GlobeNewswire - Wed Jun 08, 5:00AM CDT
Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced the following commercial update of the new Altura(R) Endovascular Stent Graft System.
EVAR: 0.94 (+0.08)
Lombard Medical to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Tue Jun 07, 1:05PM CDT
Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that CEO Simon Hubbert is scheduled to present at the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016, at 4:00 pm ET in New York City.
EVAR: 0.94 (+0.08)
Lombard Medical Receives Australian Therapeutic Goods Administration (TGA) Approval for the Aorfix(TM) Endovascular Stent Graft for the Treatment of Abdominal Aortic Aneurysms
GlobeNewswire - Mon Jun 06, 5:00AM CDT
Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that the Australian Therapeutic Goods Administration (TGA) has approved the Aorfix(TM) Endovascular Stent Graft for inclusion on the Australian Register of Therapeutic Goods. The TGA has approved the use of Aorfix for the treatment of abdominal aortic aneurysms (AAAs) with aortic neck angulations up to 90 degrees.
EVAR: 0.94 (+0.08)
Lombard Medical Announces Scientific Presentation on Aorfix(TM) Endovascular Stent Graft Five-Year Clinical Data at the 2016 Society for Vascular Surgery Annual Meeting
GlobeNewswire - Thu Jun 02, 5:00AM CDT
Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that its Aorfix(TM) Endovascular Stent Graft will be featured in a scientific presentation at the 2016 Vascular Annual Meeting of the Society for Vascular Surgery (SVS) to be held at the Gaylord National Resort & Convention Center in National Harbor, Maryland, June 8-11, 2016. Aorfix is the first and only endovascular stent graft with global approvals for the treatment of patients with aortic neck angulations up to 90 degrees.
EVAR: 0.94 (+0.08)
Lombard Medical Reports 2016 Second Quarter, Six-Month Financial Results and Provides Update on Strategic Initiatives
GlobeNewswire - Mon Aug 22, 3:00PM CDT
Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs), today reported financial results, provided business highlights for the second quarter and six months ended June 30, 2016, and announced a significant operational restructuring and the exploration of strategic alternatives to enhance shareholder value.
EVAR: 0.94 (+0.08)
Lombard Medical Reschedules 2016 Second Quarter, Six-Month Financial Results Release and Conference Call Date to August 22 to Provide Complete Information on Operational Initiatives
GlobeNewswire - Fri Aug 12, 3:00PM CDT
Lombard Medical, Inc. (Nasdaq:EVAR), a medical device company focused on Endovascular Aortic Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that it has rescheduled the date to report its 2016 Second Quarter, Six-Month Financial Results to Monday, August 22, 2016, in order to provide complete information on operational initiatives that are underway, but will not be fully implemented until next week. In addition to details on those initiatives, management will discuss financial results and provide a business update on a conference call with the investment community at 4:30 p.m. Eastern Time on Monday, August 22, 2016. Note that as a foreign private issuer, Lombard is not subject to the quarterly reporting requirements of the Securities and Exchange Commission and as such, is not subject to SEC quarterly reporting timelines.
EVAR: 0.94 (+0.08)
Lombard Medical Announces 2016 Second Quarter, Six-Month Financial Results Release and Conference Call Date
GlobeNewswire - Mon Aug 08, 5:00AM CDT
Lombard Medical, Inc. (Nasdaq:EVAR), a medical device company focused on Endovascular Aortic Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that it will release its 2016 second quarter and six-month financial results after the market closes on Monday, August 15, 2016. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Monday, August 15, 2016, to discuss financial results and provide a business update.
EVAR: 0.94 (+0.08)
Lombard Medical Announces CE Mark Approval for IntelliFlex(TM) LP Delivery System for the Aorfix(TM) Abdominal Aortic Aneurysm Endovascular Stent Graft
GlobeNewswire - Mon Jun 20, 11:29AM CDT
Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that it has received CE Mark approval for its IntelliFlex(TM) Low Profile (LP) Delivery System for the Aorfix(TM) Endovascular Stent Graft. This new and innovative system will be used for the delivery of the Aorfix endovascular stent graft, the only AAA stent graft with global approval to treat aortic neck angulation up to 90 degrees. The Company plans to begin shipments in July to its direct markets in the UK and Germany, and expects a full commercial launch in the other European markets later in the year.
EVAR: 0.94 (+0.08)
Lombard Medical Reports Positive Five-Year Aorfix(TM) Endovascular Stent Graft Clinical Results in AAA Patients with Challenging Anatomy
GlobeNewswire - Mon Jun 13, 5:00AM CDT
Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced positive clinical results from The Prospective Aneurysm Trial: High Angle Aorfix(TM) Bifurcated Stent Graft (PYTHAGORAS trial) at the 2016 Society for Vascular Surgery Annual Meeting in National Harbor, Maryland. The PYTHAGORAS trial is a prospective, controlled, multicenter U.S. trial designed to evaluate the safety and effectiveness of the Aorfix endograft for the treatment of highly angulated aortic necks or tortuous aortoiliac anatomy.
EVAR: 0.94 (+0.08)
Lombard Medical Provides Update on Controlled Launch of the New Altura(R) Endovascular Stent Graft in Europe
GlobeNewswire - Wed Jun 08, 5:00AM CDT
Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced the following commercial update of the new Altura(R) Endovascular Stent Graft System.
EVAR: 0.94 (+0.08)
Lombard Medical to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Tue Jun 07, 1:05PM CDT
Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that CEO Simon Hubbert is scheduled to present at the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016, at 4:00 pm ET in New York City.
EVAR: 0.94 (+0.08)
Lombard Medical Receives Australian Therapeutic Goods Administration (TGA) Approval for the Aorfix(TM) Endovascular Stent Graft for the Treatment of Abdominal Aortic Aneurysms
GlobeNewswire - Mon Jun 06, 5:00AM CDT
Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that the Australian Therapeutic Goods Administration (TGA) has approved the Aorfix(TM) Endovascular Stent Graft for inclusion on the Australian Register of Therapeutic Goods. The TGA has approved the use of Aorfix for the treatment of abdominal aortic aneurysms (AAAs) with aortic neck angulations up to 90 degrees.
EVAR: 0.94 (+0.08)
Lombard Medical Announces Scientific Presentation on Aorfix(TM) Endovascular Stent Graft Five-Year Clinical Data at the 2016 Society for Vascular Surgery Annual Meeting
GlobeNewswire - Thu Jun 02, 5:00AM CDT
Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that its Aorfix(TM) Endovascular Stent Graft will be featured in a scientific presentation at the 2016 Vascular Annual Meeting of the Society for Vascular Surgery (SVS) to be held at the Gaylord National Resort & Convention Center in National Harbor, Maryland, June 8-11, 2016. Aorfix is the first and only endovascular stent graft with global approvals for the treatment of patients with aortic neck angulations up to 90 degrees.
EVAR: 0.94 (+0.08)
